Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
4519 | Tokyo | JPY | Delayed | |
CHGCY | OTC Markets | USD | Delayed | |
4519 | Frankfurt | EUR | Delayed |
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
Name | Age | Since | Title |
---|---|---|---|
Osamu Nagayama | 75 | 1989 | Honorary Chairman & Senior Advisor |
Osamu Okuda | 59 | 2014 | President, CEO & Representative Director |
Henry L. Nordhoff | 81 | - | Chairman of the International Advisory Council |
Victor Halberstadt | - | - | Member of the International Advisory Council |
Franz Bernhard Humer | 77 | 2014 | Member of the International Advisory Council |
Andrew C. von Eschenbach | 81 | - | Member of the International Advisory Council |
Sonosuke Kadonaga | 71 | - | Member of the International Advisory Council |
William A. M. Burns | 76 | - | Member of the International Advisory Council |
Virginia Hilda Brunette Maxwell Bottomley | 75 | - | Member of the International Advisory Council |
Andre S. Hoffmann | 65 | - | Member of the International Advisory Council |
Arnold J. Levine | 83 | - | Member of the International Advisory Council |
Christoph Franz | 63 | 2017 | Non-Executive Director |
Fumio Tateishi | 74 | 2023 | Outside Independent Director |
Teresa A. Graham | 50 | 2023 | Director |
Hideo Teramoto | 63 | 2023 | Outside Independent Director |
Mariko Y. Momoi | 75 | 2020 | Outside Independent Non-Executive Director |
James H. Sabry | 65 | 2019 | Non-Executive Director |
Kenichi Masuda | 61 | 2020 | Outside Independent Audit & Supervisory Board Member |
Mami Yunoki | 61 | 2024 | Audit & Supervisory Board Member |
Yumiko Waseda | 64 | 2023 | Outside Independent Audit & Supervisory Board Member |
Hitoshi Itakura | 54 | - | Director |
Iwaaki Taniguchi | 57 | 2022 | Executive VP, Head of Finance Supervisory Division, CFO & Director |
Yoshiaki Ohashi | 64 | 2015 | SVP & Full-time Audit Supervisory Board Member |
Shigehiro Yamada | 60 | 2023 | Head of Sustainability Department and Full-Time Audit & Supervisory Board Member |
Hitoshi Iikura | 54 | 2024 | VP, Head of Research Division & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review